Targeting the cytochrome bc1 complex for drug development in M. tuberculosis: review

Mol Divers. 2022 Oct;26(5):2949-2965. doi: 10.1007/s11030-021-10335-y. Epub 2021 Nov 11.

Abstract

The terminal oxidases of the oxidative phosphorylation pathway play a significant role in the survival and growth of M. tuberculosis, targeting these components lead to inhibition of M. tuberculosis. Many drug candidates targeting various components of the electron transport chain in M. tuberculosis have recently been discovered. The cytochrome bc1-aa3 supercomplex is one of the most important components of the electron transport chain in M. tuberculosis, and it has emerged as the novel target for several promising candidates. There are two cryo-electron microscopy structures (PDB IDs: 6ADQ and 6HWH) of the cytochrome bc1-aa3 supercomplex that aid in the development of effective and potent inhibitors for M. tuberculosis. In recent years, a number of potential candidates targeting the QcrB subunit of the cytochrome bc1 complex have been developed. In this review, we describe the recently identified inhibitors that target the electron transport chain's terminal oxidase enzyme in M. tuberculosis, specifically the QcrB subunit of the cytochrome bc1 complex.

Keywords: Cytochrome bc 1 complex; Oxidative phosphorylation pathway; Q203; QcrB inhibitors; QcrB subunit; Terminal oxidase.

Publication types

  • Review

MeSH terms

  • Cryoelectron Microscopy
  • Cytochromes / metabolism
  • Cytochromes / pharmacology
  • Drug Development
  • Electron Transport
  • Humans
  • Mycobacterium tuberculosis*
  • Oxidoreductases / metabolism
  • Oxidoreductases / pharmacology
  • Tuberculosis* / drug therapy

Substances

  • Cytochromes
  • Oxidoreductases